BeiGene’s Tislelizumab Receives NMPA’s Approval for the Treatment of Recurrent or Metastatic Nasopharyngeal Cancer
- The approval was based on the P-III (RATIONALE 309) study evaluating the efficacy & safety of tislelizumab + gemcitabine & cisplatin vs PBO + gemcitabine & cisplatin in 256 patients with recurrent or metastatic NPC
- The trial met its 1EPs of PFS at the planned interim analysis. In updated efficacy analyses at a median follow-up of 15.5mos., tislelizumab + CT showed PFS benefit, positive trend in OS & improvement in time to disease progression or death after next-line therapy
- The safety profile was manageable & consistent with the safety profiles of each treatment agent & the results were presented at ASCO 2022. The 2EPs include ORR ORR, DoR, OS, PFS, time to second objective disease progression, and safety
Ref: Businesswire Image: BeiGene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].